Guangzhou Daguang Pharmaceutical Co., Ltd.

Primary objective: To use melogabalin besylate tablets developed by Guangzhou Daguang Pharmaceutical Co., Ltd. as the test preparation and melogabalin besylate tablets (trade name: Tarlige®) produced by Daiichi Sankyo Co., Ltd. as the reference preparation, to investigate the pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and fed state, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To evaluate the safety of the test preparation and reference preparation of melogabalin besylate tablets after a single oral administration in fasting/fed state in healthy Chinese participants.

A randomized, open-label, single-dose, two-cycle, two-crossover bioequivalence study of baricitinib tablets in healthy subjects under fasting condition

The main purpose of the study is to study the pharmacokinetics of the test preparation dapagliflozin metformin extended-release tablets (I) (specification: 10 mg/1000 mg, produced by Chongqing Boteng Pharmaceutical Co., Ltd.) and the reference preparation dapagliflozin metformin extended-release tablets (I) (Xigduo® XR, specification: 10 mg/1000 mg, produced by AstraZeneca Pharmaceuticals LP) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation dapagliflozin metformin extended-release tablets (I) (specification: 10 mg/1000 mg) and the reference preparation dapagliflozin metformin extended-release tablets (I) (Xigduo® XR, specification: 10 mg/1000 mg) in healthy adult subjects.